Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
Description:AS ATTACHED , Claims:AS ATTACHED
| # | Name | Date |
|---|---|---|
| 1 | 202318077753-STATEMENT OF UNDERTAKING (FORM 3) [15-11-2023(online)].pdf | 2023-11-15 |
| 2 | 202318077753-Sequence Listing in txt [15-11-2023(online)].txt | 2023-11-15 |
| 3 | 202318077753-Sequence Listing in PDF [15-11-2023(online)].pdf | 2023-11-15 |
| 4 | 202318077753-REQUEST FOR EXAMINATION (FORM-18) [15-11-2023(online)].pdf | 2023-11-15 |
| 5 | 202318077753-POWER OF AUTHORITY [15-11-2023(online)].pdf | 2023-11-15 |
| 6 | 202318077753-FORM 18 [15-11-2023(online)].pdf | 2023-11-15 |
| 7 | 202318077753-FORM 1 [15-11-2023(online)].pdf | 2023-11-15 |
| 8 | 202318077753-DRAWINGS [15-11-2023(online)].pdf | 2023-11-15 |
| 9 | 202318077753-DECLARATION OF INVENTORSHIP (FORM 5) [15-11-2023(online)].pdf | 2023-11-15 |
| 10 | 202318077753-COMPLETE SPECIFICATION [15-11-2023(online)].pdf | 2023-11-15 |
| 11 | 202318077753-RELEVANT DOCUMENTS [04-09-2024(online)].pdf | 2024-09-04 |
| 12 | 202318077753-FORM 13 [04-09-2024(online)].pdf | 2024-09-04 |